Tolerogenic dendritic cells, a class of immune cells engineered to suppress inflammation, may inadvertently hand human cytomegalovirus a place to hide. That finding comes from new research examining how HCMV exploits the functional state of these specialized cells.
The work matters because HCMV, a widespread herpesvirus, persists silently in most infected people yet can turn deadly for immunocompromised patients and transplant recipients. Scientists have long sought to understand how the virus evades immune detection. Meanwhile, tolDCs have gained attention as therapeutic tools for autoimmune diseases and transplant tolerance. Their potential vulnerability to viral infection raises fresh questions about clinical safety.
Researchers from TWINCORE tested tolDCs generated through three distinct protocols. Cells treated with dexamethasone alone, or dexamethasone combined with vitamin D3, resisted maturation signals. Vitamin D3 treated cells retained some responsiveness. Jennifer Becker, formerly a postdoc in the lab and now Scientific Coordinator at the Helmholtz Institute for Translational AngioCardioScience, emphasized that tolDCs do not represent a uniform population. Their characteristics vary significantly depending on the protocol and the individual donor.
As a result, the team discovered that HCMV infected tolDCs more readily than conventional monocyte derived dendritic cells. Yet despite that higher susceptibility, infected tolDCs showed poor capacity to activate T cells. They displayed fewer surface molecules for presenting viral components and reduced costimulatory markers needed for T-cell activation. Consequently, tolDCs triggered markedly weaker proliferation of both CD4+ and CD8+ T cells compared with conventional dendritic cells.
Katharina Rahmel-Stein noted the paradoxical outcome: tolDCs offer a favorable environment for HCMV while simultaneously failing to mount effective antiviral T-cell responses. Ulrich Kalinke, Executive Director of TWINCORE, added that the virus likely benefits from this diminished immune-stimulatory capacity.
Whether similar cell populations contribute to HCMV infection and immune evasion in humans remains an open question. Pinpointing which immune cells prove most vulnerable could unlock more targeted therapeutic strategies.











